Close menu




August 25th, 2025 | 07:10 CEST

Massive UNDERVALUATION?! Bayer, SFC Energy, Veganz Group

  • Vegan
  • Food
  • Sustainability
  • Pharma
  • renewableenergies
  • Energy
Photo credits: pixabay.com

Massive undervaluation of Veganz shares? The transformation from a vegan food supplier to a foodtech company is increasingly taking shape. The first shipment of oat milk, produced using a revolutionary process, is about to be delivered to the US, and analysts see EUR 160 million in revenue potential. The real question is: When will the target price and the share price rise? Bayer shares have risen surprisingly strongly this year. Investors have largely ignored problem areas. But now a rating agency is pointing out the weaknesses, and analysts remain cautious. Investors were bullish on SFC Energy. Then came the forecast adjustment, and the share price plummeted. Now, a multi-million euro order is helping to stabilize the situation.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , SFC ENERGY AG | DE0007568578 , VEGANZ GROUP AG | DE000A3E5ED2

Table of contents:


    Veganz Group: Shares massively undervalued?

    Veganz Group shares have the potential for strong performance in the coming months. The Company's transformation from a vegan food supplier to a foodtech company is taking shape. mwb research recommends buying the shares, which are trading at around EUR 16, with a price target of EUR 21.50. However, this is likely to be just the beginning, as the forecasts for the coming years have not yet been adjusted. For the coming year, for example, analysts expect revenue of EUR 37.4 million. However, this is likely to be far too low, given the latest company announcement.

    The wholly owned subsidiary Mililk FoodTech GmbH is expected to deliver its oat milk, produced using a revolutionary 2D printing process, to the US for the first time in September. The oat milk is delivered to customers in dried slices and then liquefied there. The product is suitable for large customers such as restaurant and coffee house chains, for example, but will also be offered in food retail outlets in the future. According to the Company, the short-term order forecast already amounts to 15 million liters of oat milk. Over the next 18 months, demand in North America and Asia alone is expected to reach 160 million liters. Analysts at mwb estimate revenue per liter at EUR 1. As a reminder, the official revenue estimate for 2026 is currently EUR 37.4 million.

    Due to the huge potential overseas, Veganz is looking for a production site in the US. Local production could start as early as the first half of 2026. Oat milk is just the beginning. Mililk's goal is to make plant-based beverages available worldwide efficiently and sustainably. In the past, the management board had repeatedly reported that large investors wanted to invest in Mililk. Now things are becoming more concrete: To accelerate growth, the Company is in final negotiations with strategic investors. Mililk is valued at EUR 80 million. For context: The Veganz Group is valued at less than EUR 40 million, achieved a net profit (EAT) of EUR 23.65 million in the first half of 2025, and has other exciting subsidiaries. This suggests that the stock is massively undervalued.

    This undervaluation is also recognized by the future Veganz CEO, Rayan Tegtmeier. In a recent interview with Lyndsay Malchuk, he provides fascinating insights into the expansion strategy.

    https://youtu.be/s6kQ9JvjaX8?si=-sWbTgCEovsDtWo4

    Bayer: Fitch rubs salt into the wound

    Was the Bayer share significantly undervalued at EUR 20? Looking at the share price performance in the current year, it would appear so. After all, despite the lawsuits in the US and a narrow pharmaceutical pipeline, the share price has gained almost 50% in recent months. Investors have largely ignored the legal risks in the US, which remain difficult to assess, and believe in a turnaround in the pharmaceuticals division.

    Fitch analysts have confirmed their BBB credit rating with a stable outlook for the DAX-listed company. However, the experts pointed to the high level of debt and legal risks. Shareholders should also take the reference to low cash flow seriously, which is suffering from low margins and high restructuring and legal costs.

    Stock analysts have recently been cautious in their comments. Jefferies confirmed its "Hold" recommendation with a price target of EUR 25. At least there are signs that the legal risks surrounding the PCB cases in the US are coming to an end. The latest settlements are covered by existing provisions. However, appeals are still pending in other cases. UBS also sees the fair value of Bayer shares slightly below the current price level. Analysts rate the stock as "Neutral" with a price target of EUR 28.

    SFC Energy: Order from Canada

    SFC Energy shares are currently working on bottoming out after the crash a few weeks ago. The latest order comes at just the right time to defend the EUR 16 mark. Canadian partner Latium Technologies has placed a follow-up order with SFC Energy for fuel cells and methanol tank cartridges worth CAD 1.2 million.

    Latium offers AI-powered solutions with 24/7 live monitoring for industrial and heavy industrial sites such as construction sites, mines, oil and gas production facilities, and pipelines. The devices are powered by solar modules in combination with fuel cells from SFC. Latium President Antonio Pecorilli commented: "Our mission is to redefine safety on construction sites with intelligent, autonomous, and environmentally friendly systems. SFC's EFOY Pro fuel cells are an important part of our hybrid energy concept and enable us to operate without interruption even in the most remote and power-deficient locations. As we expand our AI-driven CCTV solutions in Canada, SFC remains a reliable partner for sustainable energy efficiency."


    By reducing its annual forecast, SFC has lost a lot of confidence. It will likely need significantly more orders of this type to get back on track. In contrast, Veganz shares appear to be massively undervalued. The value of the subsidiary Mililk alone significantly exceeds the current market capitalization of the entire group. Bayer has performed strongly in the current year. Perhaps the time has come to take profits.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on September 1st, 2026 | 07:45 CEST

    Potential Moderna-Style Share Surge? Takeover Candidates Evotec, Valneva and Vidac Pharma in Focus — Analysts Bullish

    • Biotechnology
    • Pharma
    • Innovations
    • Oncology

    Moderna has shaken up the biotech market with its breakthrough in the fight against skin cancer. Partner Merck has received somewhat less attention in the coverage, despite preparing for the eventual patent expiration of one of its blockbuster drugs. Other pharmaceutical companies will also need to replenish their pipelines in the coming years. As a result, the takeover merry-go-round is likely to pick up speed again, potentially electrifying investors. One hot candidate is Vidac Pharma. Recruitment for its Phase 2B trial into high-risk actinic keratosis, a precancerous skin condition, has been completed. The results could provide a catalyst for the stock. Valneva's share price has recently risen sharply. Could its partner Pfizer eventually make a move? Analysts are recommending the stock. And what about perennial takeover candidate Evotec? Shareholders and potential buyers are currently giving the share a wide berth. Yet there is a "Buy" recommendation on the table.

    Read

    Commented by Armin Schulz on September 1st, 2026 | 07:10 CEST

    Nordex, RE Royalties & E.ON: Three Ways to Profit from the Global Renewable Energy Grid Expansion

    • royalties
    • dividends
    • renewableenergy
    • Energy
    • GridExpansion

    The global energy landscape is changing rapidly, as reflected in record levels of renewable energy capacity additions on both sides of the Atlantic. While wind power generation in Germany is reaching historic levels and grid expansion is accelerating, in North America the rising demand for electricity from data centres and generous subsidy schemes are driving a massive expansion in generation capacity. For investors, there are various investment opportunities along the renewable energy value chain. Today, we take a closer look at three companies that aim to capitalize on the global megatrend toward renewable energy: Nordex, RE Royalties and E.ON.

    Read

    Commented by Stefan Bode on September 1st, 2026 | 07:00 CEST

    Special Situations on the Stock Market: Three Stories, One Common Thread — Delivery Hero, Nemetschek, Zefiro Methane and Uber Technologies

    • methane
    • OrphanWells
    • AI
    • Software
    • Technology
    • Food

    Created and published on behalf of Zefiro Methane

    Takeover premiums, restructuring and infrastructure trends, as well as AI-driven shifts in market sentiment, can have a major short-term impact on share prices. Yet behind the headlines in the financial press, the fine print often determines where a stock goes next. Key factors include the time until a takeover is completed, regulatory approval and execution risks, cash flow quality and valuation relative to industry peers. These key factors explain why opportunities on the stock market are rarely "free". However, investors who understand how these dynamics work can better assess both the associated risks and the potential returns.

    Read